ClinicalTrials.gg
RecruitingNCT06175429PREDICTUpdated Dec 18, 2023

Prognostic Value of Exhaled Isoprene Levels for Morbidity and Functional Outcome in Cardiosurgical Patients

An observational study in Frailty, Muscle Weakness and Volatile Organic Compounds, sponsored by University of Rostock. Recruiting at 1 site in Germany. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by University of Rostock · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
66
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Frailty with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Frailty · Germany.

Planned enrollment
17th of 20
66 · median 203
Started
2023
with 2 others
Observational
20 of 33
6 open now
Registered
27th of 33
by date

Among the 33 studies in Frailty with a site in Germany, this one is the 17th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2023, is one of 20 observational ones, and was the 27th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

7 of the 33 studies in Frailty with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Frailty with a site in Germany, or all of them as a file.
02

Study summary

The perioperative preservation of functionality and quality of life plays an increasingly important role in older physically limited and frail patients undergoing cardiac surgery. Hereby, impairments of the skeletal muscle system integrity often contributes to a reduced physical performance. Early identification of these high-risk patients could help to initiate appropriate preventive and therapeutic measures. Volatile organic compounds (VOC) represent a non-invasive and real-time measurable approach for recording physiological and pathophysiological processes. Isoprene (2-methyl-1,3-butadiene) is one of the most abundantly exhaled VOCs and has recently been shown to originate from skeletal muscle metabolism. However, the prognostic value of isoprene as a volatile biomarker for skeletal muscle integrity, physical performance and functional outcome in patients undergoing cardiac surgery has not been evaluated before.

Read the detailed description

This is a single center prospective observational study evaluating exhaled isoprene as a perioperative volatile biomarker of skeletal muscle integrity, physical performance and functional outcome in cardiosurgical patients. All study participants will be assessed by comprehensive clinical examinations, laboratory testing, breath analysis and skeletal muscle ultrasound before, during as well as five and thirty days after surgery. Clinical assessments will be performed using established clinical scores and scales (e.g. the Short Physical Performance Battery and the Fried Frailty Index). Laboratory testing comprises a broad panel of blood-based biomarkers of skeletal muscle integrity and metabolism.

The investigators hypothesize that:

  • perioperative exhaled isoprene levels correlate with postoperative measures of physical performance, functional outcome and morbidity
  • perioperative exhaled isoprene levels differ between patients with and without physical frailty
  • perioperative exhaled isoprene levels correlate with sonographic and laboratory parameters of skeletal muscle integrity
03

Conditions studied

  • Frailty
  • Muscle Weakness
  • Volatile Organic Compounds
  • Isoprene
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing elective cardiac surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 65 years
  • planned cardiac surgery
  • operation duration >60 min

Exclusion criteria

Exclusion Criteria:

  • refusal of study participation
  • emergency / urgent surgery
  • acute myocardial infarction
  • acute or chronic infection
  • Pre-existing illness with permanent restriction of mobility
  • Pre-existing neuromuscular disease
  • current malignant disease
  • terminal renal insufficiency
  • severe liver cirrhosis
  • severe obstructive pulmonary disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
66 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Cardiac surgery

    Patients undergoing elective cardiac surgery

    Diagnostic Test: Physical performance testing · Diagnostic Test: Breath sampling and VOC analysis · Diagnostic Test: Muscle ultrasound · Diagnostic Test: Blood-based biomarker analysis

Interventions

  • Diagnostic testPhysical performance testing

    Assessment of physical performance using established clinical tests and scoring systems

  • Diagnostic testBreath sampling and VOC analysis

    Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.

  • Diagnostic testMuscle ultrasound

    Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.

  • Diagnostic testBlood-based biomarker analysis

    Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)

06

What researchers measure

Primary outcomes

  1. Short Physical Performance Battery

    Assessment of patient's physical performance using the Short Physical Performance Battery (SPPB, Score, scales 0-12), whereby a higher SPPB corresponds to a better physical performance.

    Time frame: day 5 after surgery

Secondary outcomes

  1. Cumulated Ambulation Score

    Assessment of functional patient outcome using the Cumulated Ambulation Score (CAS, Score, scales 0-6), whereby a higher CAS corresponds to a better functional outcome.

    Time frame: days 5 and 30 after surgery

  2. Morbidity

    Assessment of the cumulative number of postoperative complications after surgery.

    Time frame: day 30 after surgery

  3. Isoprene concentration in patients with and without frailty

    Comparison of exhaled isoprene levels (concentrations, part per billion volume - ppbV) measured by PTR-TOF between patients with and without physical frailty.

    Time frame: day 5 after surgery

  4. Medical Research Council Sum Score

    Assessment of general muscle strength of study participants using the Medical Research Council Sum Score (MRCSS, Score, scales 0-60), whereby a higher MRCSS corresponds to a higher muscle strength.

    Time frame: day 5 after surgery

  5. Muscle thickness

    Assessment of muscle thickness (mm) using muscle ultrasound in eight different limb skeletal muscles.

    Time frame: day 5 after surgery

  6. Concentrations of blood-based biomarkers

    Assessment of blood-based biomarker concentrations (pmol/l) of skeletal muscle integrity and metabolism.

    Time frame: day 5 after surgery

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Rostock University Medical Center
    Rostock, Mecklenburg-Vorpommern 18057, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2025, 22 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 22 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 18, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Oct 1, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06175429
Lead sponsor
University of Rostock
Collaborators
Prof. Dr. Daniel A. Reuter, Head of Department, Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Rostock University Medical Center, Prof. Dr. Christian D. Etz, Head of Department, Department of Cardiac Surgery, Rostock University Medical Center, PD Dr. Johannes Ehler, Consultant, Department of Anesthesiology and Intensive Care Medicine, University Hospital Jena
Responsible party
Felix Klawitter, MD (Dr. med. Felix Klawitter, DESAIC, University of Rostock) — Principal investigator
First posted
Dec 18, 2023
Start date
Nov 27, 2023
Primary completion
Oct 1, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 18, 2023

Study contacts

Felix Klawitter, Dr. med.
Contact
felix.klawitter@med.uni-rostock.de
+49381494146382
Felix Klawitter, Dr. med.
principal investigator · Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Rostock University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion